Category: Politics and Regulation

Chiropractor

Cracking Down on Chiropractic Pseudoscience

A recent CBC News investigation reveals the common pseudoscientific claims and quackery of Manitoba chiropractors.

/ March 22, 2017
497736998_7b692c5a3f_z

Melatonin: What’s on the label isn’t in the bottle

Melatonin is taken by millions each year. But does it work? Is it safe? And can you trust the label?

/ March 9, 2017
Stanislaw Burzynski, pretending to do science.

The Texas Medical Board lets Stanislaw Burzynski off lightly: A cautionary tale of the failure of regulating medicine

After three years and countless twists and turns, the final decision by the Texas Medical Board on the sanctions to be imposed on Houston cancer quack Dr. Stanislaw Burzynski were announced on Friday. Sadly, they were not enough. The Burzynski saga should serve as a cautionary tale that the regulation of physicians and medicine is too lax, not too strict.

/ March 6, 2017
Chemotherapy Patient

Bills remove impediments to ill-advised state “right to try” laws, shield wrongdoers, and hide adverse events

Congressional bills will unleash state "right to try" laws, block terminally ill patients from redress for damages caused by negligent doctors and drug companies, and hide adverse drug events from the public.

/ March 2, 2017
Food_supplements

Bring on the Evidence: A new regulatory approach to CAM

Complementary and alternative medicine is popular, but it's poorly regulated, and most products lack good evidence of efficacy. A new approach proposed in Australia may help consumers make more informed, science-based health decisions.

/ February 23, 2017
Map_of_USA_showing_state_names

Turning chiropractors into primary care physicians via Legislative Alchemy

Via the magic of Legislative Alchemy, chiropractic lobbyists are trying to to convince state legislators to expand chiropractic scope of practice so they can rebrand as primary care physicians.

/ February 16, 2017
FTC

Regulating Health Care Products

How should we optimally regulate health care products to protect consumers? A conversation with the Acting Chairman of the FTC.

/ February 15, 2017
Donald Trump, Mike Pence, Andrew Wakefield, and Robert F. Kennedy, Jr.

In 2017, are antivaxers winning?

The election of Donald Trump as President has emboldened antivaxers, because they quite rightly sense that he is one of them. His inauguration as President, combined with other trends, have led observers to ask the question: Are antivaxers winning, or will 2017 be the year of the antivaxer?

/ February 13, 2017
Translational research and preclinical data

Donald Trump versus the FDA: Is the standard of evidence for drug approval actually too low rather than too high?

All of the candidates being considered by President Trump for FDA Commissioner believe that the FDA is too strict in its standards for approving new drugs. In a commentary in Nature last week, two bioethicists argued that, at least in terms of preclinical data, the standard of evidence is actually too low. Which is correct?

/ February 6, 2017